BIONi010-C-12 66541076-1VL

Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to an embryonic stem cell–like state. The cells can replicate indefinitely or, under controlled conditions, can be differentiated into any other cell type such as nerve, heart or liver cells. Medical researchers are able to use iPS cells to test how different patients might respond to new drugs or to analyse how genetic diseases develop.
The EBiSC stem cell bank, is a collection of human iPS cells available to academic and commercial researchers for use in disease modelling and other forms of stem cell research. The initial collection has been generated from a wide range of donors representing specific disease backgrounds and healthy controls. EBiSC has established many routine procedures for collecting, expanding and characterizing human iPS cell lines. The stem cell bank includes iPSC cell lines derived from neurodegenerative diseases (Alzheimers Disease, Parkinsons Disease, Dementia, Motor Neuron Disease (ALS) - and Huntingtons Disease), eye and heart diseases, and lines from healthy control donors for age and sex matching.
Depositor
Bioneer
Derivation
Primary cell type: -
Reprogramming method
Vector type: Non-integrating
Vector: Episomal
Is the reprogramming vector detectable: No
Merthods used: pcr
Xeno free conditions: no
Derived under gmp: no
Available as clinical grade: no
Characterization
Microbiology / Virus Screening
HIV 1: -
HIV 2: -
Hepatitis B: -
Hepatitis C: -
Mycoplasma: Negative

Genotyping
Karyotyping
Passage number: 12
Cell line karyotype: 46, XY
Karyotyping method: G-Banding
Image / Result
Genetic Modification
Disease/phenotype related modifications
Disease: MODY
Type of modification: Isogenic
Gene: HNF4A
Chromosome location: 20q13.12
Nucleotide sequence HGSV: NM_175914.4:c.925C>T
Protein sequence HGSV: NP_787110.2:p.(p.Arg309Cys)
Zygosity: Homozygous
Target locus modification: Mutated
Description: A Cytocine to Tyrosine mutation was introduced into both alleles of exon 8 in HNF4A resulting in a mutation previously shown to cause MODY1 in patients.

Additional Cell Line Info,

EBiSC Access Use Agreement (EAUA),

Cell Line Information Pack (CLIP),

Note: EAUA and CLIP must be completed before order fulfillment
Surface coating: Matrigel®/Geltrex®
Passage method: Enzyme-free cell dissociation / EDTA
O2 concentration: 20%
CO2 concentration: 5%
Culture medium: mTeSR® 1
Passage Number banked (pre-EBiSC): 12
No. Vials banked (pre-EBiSC): 4
EBiSC is a trademark of Fraunhofer-Gesellschaft
GELTREX is a registered trademark of Life Technologies Corporation
Matrigel is a registered trademark of Corning, Inc.
mTeSR is a registered trademark of WiCell Research Institute, Inc.

biological source	human
reprogramming method	episomal
description	age (N/A)
Торговая марка	EBiSC™
gender	male
growth mode	adherent (pluripotent)
application(s)	cell culture | stem cell: suitable
relevant disease(s)	none
shipped in	dry ice
storage temp.	196°C

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point F	Not applicable
Flash Point C	Not applicable